Dynamic Technology Lab Private Ltd Sells 7,412 Shares of Definitive Healthcare Corp. (NASDAQ:DH)

Dynamic Technology Lab Private Ltd lowered its holdings in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 35.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 13,326 shares of the company’s stock after selling 7,412 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Definitive Healthcare were worth $55,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in shares of Definitive Healthcare by 5.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 436,132 shares of the company’s stock worth $1,950,000 after acquiring an additional 23,706 shares during the last quarter. State Street Corp increased its position in Definitive Healthcare by 29.4% during the 3rd quarter. State Street Corp now owns 1,399,729 shares of the company’s stock valued at $6,257,000 after purchasing an additional 317,952 shares during the period. XTX Topco Ltd bought a new position in Definitive Healthcare during the 3rd quarter worth approximately $93,000. Barclays PLC lifted its position in shares of Definitive Healthcare by 318.8% in the 3rd quarter. Barclays PLC now owns 81,916 shares of the company’s stock worth $366,000 after purchasing an additional 62,354 shares during the period. Finally, 272 Capital LP boosted its stake in shares of Definitive Healthcare by 74.8% in the 3rd quarter. 272 Capital LP now owns 1,114,080 shares of the company’s stock valued at $4,980,000 after purchasing an additional 476,766 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DH. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a report on Thursday, January 16th. The Goldman Sachs Group lowered their price objective on Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Barclays cut their target price on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a research report on Monday, March 3rd. Finally, Stephens began coverage on Definitive Healthcare in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 target price for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.35.

Definitive Healthcare Trading Up 4.4 %

Shares of Definitive Healthcare stock opened at $2.59 on Friday. The stock has a market capitalization of $292.44 million, a PE ratio of -0.84, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48. Definitive Healthcare Corp. has a 52 week low of $2.15 and a 52 week high of $7.66. The stock has a 50 day moving average price of $3.57 and a two-hundred day moving average price of $4.10. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.04). Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The business had revenue of $62.29 million during the quarter, compared to analyst estimates of $60.60 million. As a group, equities analysts anticipate that Definitive Healthcare Corp. will post 0.16 earnings per share for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.